Pfizer's C. difficile Vaccine Succeeds in Phase II Study
February 2nd 2017Researchers found the experimental vaccine could potentially inhibit severe diarrhea and pseudomembranous colitis by inducing a functional antibody response that can neutralize the two main disease-causing toxins (toxin A or B) produced by C. difficile.
Direct-Acting Antivirals for HCV-Associated Rheumatic Diseases
February 1st 2017In a review article published in Rheumatic Disease Clinics of North America, researchers discuss the main rheumatologic diseases associated with chronic HCV infection, and how DAAs have affected these extrahepatic manifestations.
Treatment Options for HCV Patients with Renal Impairment
February 1st 2017A research group from Hokkaido University in Japan found that standard treatment for those with genotype 1 HCV should likely be switched from interferon (INF)-based therapies to INF-free direct-acting antiviral (DAA) therapies.
New Tools to Diagnose Superbugs Called for at World Economic Forum
January 30th 2017The Joint United Nations Programme on HIV/AIDS and medical technology industry partners have announced new efforts to better diagnose bacterial infections at the recent World Economic Forum Annual Meeting in Davos, Switzerland.
Too Many Conflicts of Interest Found in HCV Management Guidelines
January 29th 2017A group of researchers recently published a study in JAMA, examining conflicts of interest (COIs) among committee members who set hepatitis C (HCV) and cholesterol management guidelines. They found that there, in fact, were COIs among committee members setting HCV management guidelines.